CHARLOTTE, N.C.--(BUSINESS WIRE)--cbdMD, Inc. (NYSE American: YCBD, YCBDpA), one of the leading and most highly trusted and recognized CBD companies, recently released a full line of drink mixes, adding to their robust offering of products. Available in four flavors including Strawberry Kiwi, Lemonade, Peach and Fruit Punch, these drink mixes can be easily dissolved into any beverage and come packed with 25 mg of CBD per packet with added vitamin C. No added sugar or caffeine, these drink mixes use Nano-Encapsulated Technology for fast, water-soluble absorption so users can experience the benefits in a quick time frame.
“We’re constantly looking for new ways to innovate within the CBD industry and offer a variety of product solutions for our customers. This new line of drink mixes makes adding CBD to a daily routine even easier, giving people the options they want to make the right decisions for a healthy lifestyle. And, we look forward to debuting even more exciting and innovative products this Fall,” said Martin Sumichrast, Chairman & co-CEO of cbdMD, Inc.
Life is a constant on-the-go for most families and working professionals, and cbdMD drink mixes make it easy to travel with and use CBD when out and about. Family and friends frequently ask about a CBD users’ experience, and this product provides a great way to share with their single use packaging.
About cbdMD, Inc.
cbdMD, Inc. is one of the world’s leading, most highly trusted health & wellness CBD companies, whose current products include CBD tinctures, CBD capsules, CBD gummies, CBD topicals, CBD botanical skincare products, CBD bath bombs and CBD pet products. To learn more about cbdMD and our comprehensive line of over 100 SKUs of U.S. produced, THC-free1 CBD products, please visit www.cbdMD.com, follow cbdMD on Instagram and Facebook, or visit one of the 6,000 retail outlets that carry cbdMD products.
This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and ''proposes.'' These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including, without limitation, statements made with respect to the expansion of the consumer market for CBD products and our ability to increase our market share, our limited operating history, our ability to expand our business and significantly increase our revenues, our ability to effectively leverage our brand partnerships and sponsorships, our ability to effectively compete in our market, our ability to achieve our net sales guidance, and our ability to report profitable operations in the future. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading "Risk Factors" in cbdMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 as filed with the Securities and Exchange Commission (the "SEC") and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.
1THC-free is defined as below the level of detection using validated scientific analytical tools.